Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

10/9/23 7:23:07 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLDI

Date	Price Target	Rating	Analyst
11/22/2023	$11.00	Buy	H.C. Wainwright
10/9/2023	$9.00	Outperform	Robert W. Baird